Table of Content

1. Conception & Ongoing Development Of Bispecific Antibody Drug Conjugates
1.1 Overview
1.2 Comparison of Bispecific Antibody Drug Conjugates With Other Immunotherapies


2. Need For Bispecific Antibody Drug Conjugates


3. Bispecific Antibody Drug Conjugates - Design & Mechanism Of Action
3.1 General Structure & Design Of Bispecific Antibody Drug Conjugates
3.2 Mechanism Of Action


4. Global Bispecific Antibody Drug Conjugates Clinical Trials Overview
4.1 By Company
4.2 By Country
4.3 By Indication
4.4 By Phase
4.5 By Target


5. Global Bispecific Antibody Drug Conjugate Market Insight
5.1 Current Market Scenario
5.2 Future Market Opportunity


6. Bispecific Antibody Drug Conjugates Market Analysis by Region
6.1 China
6.2 US
6.3 Europe
6.4 South Korea


7. Bispecific Antibody Drug Conjugates – Application & Development By Indication
7.1 Breast Cancer
7.2 Gastrointestinal Cancer
7.3 Lung Cancer
7.4 Urologic Cancers
7.5 Gynecologic Cancers


8. Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase II
8.5 Phase III


9. Platforms Technologies Used to Develop Bispecific Antibody Drug Conjugates
9.1 ABL Bio - ADC Strategy
9.2 Alphamab Oncology - Proprietary ADC Platform
9.3 Biocytogen - RenLite mice
9.4 BiVictriX - Bi-Cygni Therapeutics
9.5 Debiopharm – Multilink
9.6 Debiopharm – AbYlink?
9.7 Duality Biologics - Duality Novel Platforms
9.8 Enduring Biotech - PEGylated Bispecific ADC Technology
9.9 Innovent Biologics - Unnamed Proprietary ADC technology
9.10 Medilink - TMALIN technology platform
9.11 ProEn Therapeutics - ArtBody? ADC technology
9.12 Sichuan Baili Pharmaceutical/SystImmune – HIRE-ADC
9.13 Zymeworks - Unnamed Technology



10. Competitive Landscape
10.1 Alphamab Oncology
10.2 Amgen
10.3 AstraZeneca
10.4 Beijing Biocytogen
10.5 BiVictriX Therapeutics
10.6 Corellia AI
10.7 Debiopharm
10.8 Doma Bio
10.9 Genmab
10.10 Innovent Biologics
10.11 ProEn Therapeutics
 



List of Figures

Figure 1-1: Limitations Of Convectional Immunotherapies Addressable By BsADCs

Figure 3-1: Bispecific Antibody Drug Conjugate - General Structure
Figure 3-2: Bispecific Antibody Drug Conjugate – General Mechanism of Action

Figure 4-1: Global – Bispecific Antibody Drug Conjugates Clinical Pipeline By Company (Numbers), 2024
Figure 4-2: Global – Bispecific Antibody Drug Conjugates Clinical Pipeline By Country (Numbers), 2024
Figure 4-3: Global – Bispecific Antibody Drug Conjugates Clinical Pipeline By Indication (Numbers), 2024
Figure 4-4: Global – Bispecific Antibody Drug Conjugates Clinical Pipeline By Phase (Numbers), 2024
Figure 4-5: Global – Bispecific Antibody Drug Conjugates Clinical Pipeline By Target (Numbers), 2024

Figure 5-1: Bispecific Antibody Drug Conjugate Market Forecast – First 12 Months & First 24 Months Of Approval Of First Drug (US$ Million)

Figure 7-1: BL-B01D1-306 Phase III (NCT06343948) Study – Initiation & Estimated Completion Year
Figure 7-2: BL-B01D1-307 Phase III (NCT06382142) Study – Initiation & Estimated Completion Year
Figure 7-3: BL-B01D1-204-04 Phase II (NCT06471205) Study – Initiation & Estimated Completion Year
Figure 7-4: BL-B01D1-SI-B003-201-04 Phase II (NCT06042894) Study – Initiation & Estimated Completion Year
Figure 7-5: BL-B01D1-LUNG-101 Phase I (NCT05983432) Study – Initiation & Estimated Completion Year
Figure 7-6: BL-B01D1-104 Phase I (NCT05470348) Study – Initiation & Estimated Completion Year
Figure 7-7: KM501-1001 Phase I (NCT05804864) Study – Initiation & Estimated Completion Year
Figure 7-8: ZWI-ZW49-101 Phase I (NCT03821233) Study – Initiation & Estimated Completion Year
Figure 7-9: BL-B01D1-SI-B003-201-05 Phase II (NCT06008054) Study – Initiation & Estimated Completion Year
Figure 7-10: BL-B01D1-103 Phase I (NCT05262491) Study – Initiation & Estimated Completion Year
Figure 7-11: BL-B01D1-302 Phase III (NCT06382129) Study – Initiation & Estimated Completion Year
Figure 7-12: BL-B01D1-301 Phase III (NCT06382116) Study – Initiation & Estimated Completion Year
Figure 7-13: BL-B01D1-304 Phase III (NCT06500026) Study – Initiation & Estimated Completion Year
Figure 7-14: DM001001 Phase II (NCT06475937) Study – Estimated Initiation & Estimated Completion Year
Figure 7-15: CIBI334A101 Phase I/II (NCT05774873) Study – Estimated Initiation & Estimated Completion Year
Figure 7-16: BL-B01D1-201 Phase II (NCT05785039) Study – Initiation & Estimated Completion Year
Figure 7-17: BL-B01D1-102 Phase I (NCT05393427) Study – Initiation & Estimated Completion Year
Figure 7-18: BL-B01D1-SI-B003-201-08 Phase II (NCT05990803) Study – Initiation & Estimated Completion Year
Figure 7-19: BL-B01D1-202 Phase Ib/II (NCT05803018) Study – Initiation & Estimated Completion Year
Figure 7-20: IMGN151-1001 Phase I (NCT05527184) Study – Initiation & Estimated Completion Year
Figure 7-21: JSKN003-102 Phase I/II (NCT05744427) Study – Initiation & Estimated Completion Year

Figure 9-1: BiVictriX - Bi-Cygni Therapeutics
Figure 9-2: Duality Biologics – DITAC Platform
Figure 9-3: Duality Biologics – DITAC Platform
Figure 9-4: ProEn Therapeutics - ArtBody? ADC Technology

List of Tables

Table 5-1: Bispecific Antibody Drug Conjugate Market – Recent Collaborations
Table 7-1: BL-B01D1: Clinical Trials Underway For Lung Cancer, September’2024